X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14486) 14486
Book Review (3047) 3047
Newsletter (596) 596
Publication (477) 477
Magazine Article (82) 82
Book / eBook (53) 53
Conference Proceeding (47) 47
Newspaper Article (41) 41
Book Chapter (38) 38
Dissertation (4) 4
Trade Publication Article (4) 4
Web Resource (3) 3
Data Set (2) 2
Reference (2) 2
Transcript (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12459) 12459
humans (11160) 11160
male (7586) 7586
hyperlipidemias - drug therapy (6671) 6671
female (6028) 6028
hyperlipidemia (5463) 5463
middle aged (5100) 5100
adult (3911) 3911
aged (3153) 3153
risk factors (2999) 2999
animals (2869) 2869
triglycerides - blood (2683) 2683
cholesterol (2545) 2545
hyperlipidemias - blood (2481) 2481
hypolipidemic agents - therapeutic use (2449) 2449
cholesterol - blood (2375) 2375
hyperlipidemias - complications (2346) 2346
lipids - blood (1884) 1884
abridged index medicus (1798) 1798
lipids (1581) 1581
pharmacology & pharmacy (1569) 1569
atherosclerosis (1545) 1545
cholesterol, ldl - blood (1452) 1452
rats (1386) 1386
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1382) 1382
drug therapy (1367) 1367
medicine, general & internal (1304) 1304
treatment outcome (1255) 1255
cardiac & cardiovascular systems (1224) 1224
research (1191) 1191
diabetes (1181) 1181
statins (1137) 1137
care and treatment (1089) 1089
cholesterol, hdl - blood (1080) 1080
hypercholesterolemia (1080) 1080
cardiovascular disease (1058) 1058
risk (1031) 1031
hypertension (1012) 1012
anticholesteremic agents - therapeutic use (1010) 1010
coronary-heart-disease (990) 990
hyperlipidemias - etiology (956) 956
hyperlipidemias - metabolism (941) 941
peripheral vascular disease (909) 909
health aspects (891) 891
mice (883) 883
triglycerides (881) 881
disease (849) 849
drug therapy, combination (846) 846
lipoproteins - blood (828) 828
hyperlipidemias - therapy (820) 820
prevention (817) 817
cardiovascular-disease (805) 805
metabolism (799) 799
lipoproteins (793) 793
adolescent (786) 786
obesity (782) 782
endocrinology & metabolism (774) 774
hyperlipidemias - chemically induced (773) 773
insulin resistance (773) 773
hyperlipidemias - epidemiology (772) 772
therapy (751) 751
hypertension - drug therapy (733) 733
diet (719) 719
time factors (716) 716
cardiovascular diseases - prevention & control (705) 705
simvastatin (696) 696
hypolipidemic agents - pharmacology (692) 692
insulin-resistance (688) 688
hypercholesterolemia - drug therapy (682) 682
mortality (680) 680
myocardial-infarction (678) 678
analysis (675) 675
dyslipidemia (662) 662
atorvastatin (659) 659
cardiovascular diseases (654) 654
diabetes mellitus (653) 653
clinical trials as topic (643) 643
low density lipoproteins (637) 637
retrospective studies (631) 631
hypertension - complications (608) 608
lipoproteins, ldl - blood (589) 589
coronary heart disease (586) 586
hyperlipidemias - genetics (585) 585
coronary disease - prevention & control (577) 577
risk-factors (574) 574
double-blind method (563) 563
biochemistry & molecular biology (555) 555
diabetes mellitus, type 2 - complications (555) 555
prevalence (549) 549
hyperlipidemias - prevention & control (547) 547
physiological aspects (546) 546
lipid metabolism (543) 543
medicine & public health (536) 536
low-density-lipoprotein (531) 531
hiv infections - drug therapy (529) 529
metabolic syndrome (529) 529
oxidative stress (528) 528
liver - metabolism (526) 526
follow-up studies (523) 523
pravastatin (521) 521
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (43) 43
Online Resources - Online (4) 4
Baycrest Hospital - Wellness Library (1) 1
Bridgepoint Health - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Gerstein Science - Theses (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13342) 13342
German (418) 418
French (261) 261
Russian (194) 194
Chinese (188) 188
Japanese (184) 184
Italian (182) 182
Spanish (166) 166
Polish (95) 95
Czech (53) 53
Swedish (30) 30
Hungarian (21) 21
Norwegian (21) 21
Portuguese (21) 21
Danish (20) 20
Finnish (20) 20
Romanian (20) 20
Dutch (16) 16
Hebrew (16) 16
Turkish (7) 7
Croatian (6) 6
Serbian (6) 6
Slovak (6) 6
Bulgarian (4) 4
Lithuanian (3) 3
Ukrainian (3) 3
Korean (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 04/2007, Volume 115, Issue 14, pp. 1948 - 1967
Despite compliance with lifestyle recommendations, some children and adolescents with high-risk hyperlipidemia will require lipid-lowering drug therapy,... 
Drugs | Pediatrics | Lipids | Hypercholesterolemia | AHA Scientific Statements | FACTOR INTERVENTION PROJECT | INTIMA-MEDIA THICKNESS | DEPENDENT DIABETES-MELLITUS | lipids | CARDIAC & CARDIOVASCULAR SYSTEMS | LOW-CHOLESTEROL DIET | drugs | LOW-DENSITY-LIPOPROTEIN | RESTORES ENDOTHELIAL FUNCTION | BODY-FAT DISTRIBUTION | hypercholesterolemia | BLOOD-PRESSURE | pediatrics | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | PERIPHERAL VASCULAR DISEASE | LOW-SATURATED-FAT | Dyslipidemias - complications | Humans | Hyperlipoproteinemias - epidemiology | Middle Aged | Child, Preschool | Male | Arteriosclerosis - epidemiology | Phytotherapy | Child | Dyslipidemias - diagnosis | Metabolic Syndrome - epidemiology | Arteriosclerosis - etiology | HIV Protease Inhibitors - adverse effects | Hypolipidemic Agents - adverse effects | Arteriosclerosis - diagnostic imaging | Risk Factors | Combined Modality Therapy | Disease Progression | Arteriosclerosis - prevention & control | Diet, Fat-Restricted | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hyperlipoproteinemia Type II - diet therapy | Adolescent | Age of Onset | HIV Infections - complications | Hypolipidemic Agents - therapeutic use | Arteriosclerosis - pathology | Cholesterol, Dietary | Dyslipidemias - diet therapy | Hyperlipoproteinemias - classification | Age Factors | Hyperlipoproteinemia Type II - diagnosis | Infant | Exercise Therapy | Contraindications | Dietary Fats | Hyperlipoproteinemias - drug therapy | Ultrasonography | Diabetes Complications - epidemiology | Adult | Cholesterol, LDL - blood | Female | Anticholesteremic Agents - classification | Hyperlipoproteinemia Type II - drug therapy | Hyperlipoproteinemia Type II - complications | Dyslipidemias - drug therapy | Clinical Trials as Topic | Anticholesteremic Agents - therapeutic use | Hyperlipoproteinemia Type II - epidemiology | Obesity - epidemiology | Hypolipidemic Agents - administration & dosage | HIV Infections - drug therapy | Hyperlipoproteinemias - genetics | Care and treatment | Demographic aspects | Hyperlipidemia | Research | Drug therapy | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Drugs, ISSN 0012-6667, 2012, Volume 72, Issue 6, pp. 759 - 772
Cardiovascular disease (CVD) remains the leading cause of death and morbidity in the world. The origins of atherosclerosis and subsequent CVD begin in... 
Cholesterol-ester-transfer-protein-inhibitors | Ezetimibe | Sitosterolaemia | Cardiovascular-disorders | Hyperlipoproteinaemia-type-IIa | Niacin | Microsomal-triglyceride- transfer-protein-inhibitors | Teratogenesis | Fibric-acid-derivatives | Bile-acid-binding-protein-modulators | Atherosclerosis | Children | Adolescents | Hypercholesterolaemia | HMG-CoA-reductase-inhibitors | INTIMA-MEDIA THICKNESS | DENSITY-LIPOPROTEIN CHOLESTEROL | METABOLIC SYNDROME | LONG-TERM SAFETY | FAMILIAL COMBINED HYPERLIPIDEMIA | PHARMACOLOGY & PHARMACY | AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA | RESTORES ENDOTHELIAL FUNCTION | TOXICOLOGY | CORONARY-HEART-DISEASE | STAGE RENAL-DISEASE | CARDIOVASCULAR RISK-FACTORS | Cardiovascular Diseases - etiology | Life Style | Cardiovascular Diseases - prevention & control | Humans | Risk Factors | Child, Preschool | Hypercholesterolemia - drug therapy | Randomized Controlled Trials as Topic | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Adolescent | Cardiovascular Diseases - blood | Cholesterol, HDL - blood | Cholesterol, LDL - blood | Hypercholesterolemia - complications | Child | Anticholesteremic agents | Causes of | Cholesterol, LDL | Drug therapy | Hypercholesterolemia in children | Health aspects | Risk factors | Index Medicus | Drugs | Intervention | Physical activity | statins | Age | Morbidity | Guidelines
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2016, Volume 119, pp. 135 - 140
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 09/2013, Volume 715, Issue 1-3, pp. 246 - 255
The sodium–glucose cotransporter 2 (SGLT ) is responsible for most glucose reabsorption in the kidney and has been proposed as a novel therapeutic target for... 
Hyperglycemia | Diabetes | SGLT2 | Urinary glucose excretion | Ipragliflozin | GLYCEMIC CONTROL | MELLITUS | BETA-CELL FUNCTION | INSULIN | BODY-WEIGHT | NONALCOHOLIC FATTY LIVER | DIET | DISEASE | PHARMACOLOGY & PHARMACY | COMPLICATIONS | SODIUM-GLUCOSE COTRANSPORTER | Thiophenes - therapeutic use | Obesity - drug therapy | Fatty Liver - complications | Diet, High-Fat - adverse effects | Hyperglycemia - complications | Male | Glucosides - pharmacokinetics | Hyperglycemia - drug therapy | Inflammation - complications | Inflammation - drug therapy | Glucosides - therapeutic use | Insulin Secretion | Diabetes Mellitus, Type 2 - complications | Hyperlipidemias - complications | Hypoglycemic Agents - therapeutic use | Glucose Tolerance Test | Glucosides - pharmacology | Hypoglycemic Agents - pharmacokinetics | Glycosuria - drug therapy | Obesity - complications | Hyperlipidemias - drug therapy | Insulin Resistance | Thiophenes - pharmacology | Sodium-Glucose Transporter 2 Inhibitors | Diabetes Mellitus, Type 2 - urine | Fatty Liver - drug therapy | Hypoglycemic Agents - pharmacology | Thiophenes - pharmacokinetics | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Animals | Mice | Oxidative Stress - drug effects | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Niacinamide | Glucose metabolism | Obesity | Oxidative stress | Streptozocin | Hyperlipidemia | Blood sugar | Analysis | Insulin resistance | Index Medicus
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 10/2017, Volume 37, Issue 10, pp. 1204 - 1214
BACKGROUND The Centers for Medicare and Medicaid Services (CMS) Medicare Star program provides incentives to health plans when their patients with diabetes... 
hyperlipidemia | Medicare Star | statin | elderly | angiotensin II receptor blocker | medication adherence | angiotensin‐converting enzyme inhibitor | hypertension | angiotensin-converting enzyme inhibitor | POPULATION | RENAL-FUNCTION | CARBAMAZEPINE | SERUM | GABAPENTIN | VARIABILITY | NURSING-HOME RESIDENTS | PHARMACOKINETICS | DRUG-MONITORING DATA | PHARMACOLOGY & PHARMACY | ABSORPTION | Diabetes Mellitus - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Cardiovascular Diseases - etiology | Comorbidity | Cardiovascular Diseases - prevention & control | Humans | Risk Factors | Diabetes Mellitus - drug therapy | Male | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Medication Adherence | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Diabetes Mellitus - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Blood Pressure - drug effects | Retrospective Studies | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - administration & dosage | Cohort Studies | Hypertension | Diabetics | Medical research | Enzymes | Medicare | Low density lipoproteins | Aged patients | Patient compliance | Risk factors | Infection control | Angiotensin | Medicine, Experimental | Drug therapy | Medicaid | Statins | Diabetes therapy | Health care | Elderly people | Angiotensin-converting enzyme inhibitors | Drugs | Lipoproteins (low density) | Incentives | Blood | Confidence intervals | Enzyme inhibitors | Peptidyl-dipeptidase A | Blood pressure | Poisson density functions | Angiotensin II | Cardiovascular system | Statistical analysis | Diabetes mellitus | Health risks | Disease control | Patients | Adhesion | Low density lipoprotein | Cholesterol | Government programs | Diabetes | Risk management | Cardiovascular diseases | Mercury | Elderly | Geriatrics | Index Medicus | angiotensin converting enzyme inhibitor | angiotensin receptor blocker
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 07/2014, Volume 66, Issue 7, pp. 975 - 987
Objective Sodium-glucose cotransporter (SGLT) 2 plays an important role in renal glucose reabsorption and has been highlighted as a therapeutic target for the... 
hyperglycaemia | SGLT | diabetes | urinary glucose excretion | ipragliflozin | SGLT2 | PHLORIZIN TREATMENT | MELLITUS | FAMILY | INSULIN | PATHOGENESIS | CLONING | DISEASE | HYPOGLYCEMIA | PHARMACOLOGY & PHARMACY | EXPRESSION | Thiophenes - therapeutic use | Diabetes Mellitus, Experimental - drug therapy | Streptozocin | Male | Diabetes Mellitus, Type 1 - complications | Hyperglycemia - drug therapy | Glucose Intolerance - drug therapy | Glomerular Filtration Rate - drug effects | Liver - drug effects | Glucose Intolerance - etiology | Inflammation - drug therapy | Glucosides - therapeutic use | Diabetes Mellitus, Experimental - complications | Hypoglycemic Agents - therapeutic use | Glucosides - pharmacology | Kidney - drug effects | Albuminuria - etiology | Hyperlipidemias - drug therapy | Thiophenes - pharmacology | Inflammation - etiology | Rats, Sprague-Dawley | Fatty Liver - drug therapy | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 1 - drug therapy | Hypoglycemic Agents - pharmacology | Animals | Albuminuria - drug therapy | Hyperlipidemias - etiology | Hyperglycemia - etiology | Oxidative Stress - drug effects | Blood Glucose - metabolism | Fatty Liver - etiology | Oxidative stress | Glucose metabolism | Hyperglycemia | Type 1 diabetes | Liver | Glucose | Health aspects | Dextrose | Diabetes | Sodium | Insulin | Rodents | Index Medicus
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 5, pp. 438 - 447
Journal Article
1991, Fundamental and clinical cardiology, ISBN 9780824785123, Volume 1, xii, 270
Book